E-NEWSLETTER
-
Burgopak launch Chrysalis Carton in partnership with Medica Packaging
The solution connects the outer carton and patient information leaflet (PIL) conveniently together. The patient pulls a perforated flap on the carton to expose the patient leaflet, which they can unfold to display the product information.
E-NEWSLETTER | 21 May 2012
-
Pharmaceutical giants set to lose dominance in urological disorders market
Major pharmaceutical companies are predicted to lose their footing in the urological disorders market by 2017, a report by GBI Research has found.
E-NEWSLETTER | 17 May 2012
-
Labor L+S AG, Symbiosis form alliance
Labor L+S AG, Bad Bocklet and Symbiosis, the newly created business division of Biopharm GmbH, Heidelberg, announced that they have entered into an exclusive business alliance.
E-NEWSLETTER | 16 May 2012
-
ACM Global Central Laboratory establishes Mumbai-based subsidiary
ACM Global Central Lab has advanced its hybrid central lab model in Mumbai with an operational facility dedicated to manage clinical trials testing in India and provide study support throughout Asia Pacific.
E-NEWSLETTER | 15 May 2012
-
UCB, Domainex Collaborates
Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known as MEK), a protein which is over-active in many human cancers.
E-NEWSLETTER | 10 May 2012
-
Siro Clinpharm appoints chief executive officer
Siro Clinpharm announced the appointment of Gopakumar Menon as chief executive officer.
E-NEWSLETTER | 09 May 2012
-
Bayer HealthCare, Tsinghua University in partnership
Both partners signed a new strategic agreement to collaborate in the area of biomedical sciences over the next three years.
E-NEWSLETTER | 07 May 2012
-
Telormedix’s TMX-101 exhibits high safety in phase I/II for non-muscle invasive bladder cancer
Telormedix announced that it has successfully completed the safety portion of a Phase I/II trial for TMX-101.
E-NEWSLETTER | 04 May 2012
-
Phosphagenics signs agreement with Nippon Zoki
The companies have struck a material transfer agreement which enables Nippon Zoki to test and assess Phosphagenics’ patented TPM/diclofenac topical non-steroidal pain formulation for its suitability as a prescription item in the USA and Japanese markets.
E-NEWSLETTER | 03 May 2012
-
Aslan Pharmaceuticals selects PharmaNet/i3 as partner for oncology development
Aslan Pharmaceuticals has selected PharmaNet/i3 as a partner supporting the development of their oncology portfolio in Asia.
E-NEWSLETTER | 02 May 2012
